Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis

Autor: Hideki Iwahashi, Masashi Takano, Takahiro Sakamoto, Hiroko Matsuura, Tomoyuki Yoshikawa, Kenichi Furuya, Mika Kuwahara, Morikazu Miyamoto, Hiroaki Soyama, Kento Kato, Hiroki Ishibashi, Tadashi Aoyama, Kazuki Takasaki
Rok vydání: 2018
Předmět:
Zdroj: Cancer Chemotherapy and Pharmacology. 81:809-814
ISSN: 1432-0843
0344-5704
DOI: 10.1007/s00280-018-3552-5
Popis: To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem). Between 2011 and 2017, we identified the Bev–Gem and Gem PROC groups. The regimen included 1000 mg/m2 of Gem on days 1, 8, and 15, and 15 mg/m2 of Bev on day 1, every 4 weeks. Progression-free survival (PFS) and overall survival (OS) were calculated from the date of the administration of Bev–Gem or Gem until disease progression or death. The Bev–Gem and Gem groups included 18 and 29 patients, respectively. More patients had advanced stage disease in the Bev–Gem group (p = 0.048); no other characteristics differed between the groups. The response rates [ratio of complete remission (CR) to partial remission (PR)] of Bev–Gem and Gem were 38.9 and 3.4%, respectively (p
Databáze: OpenAIRE